Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?

PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

“…In an extension of the theories articulated by Velji et al. 21 and Sampietro et al., 22 we propose that combined treatment with PCSK9 monoclonal antibodies and apheresis may be preferable in certain hypercholesterolaemic patients with high Lp(a), because of the combined benefits of both approaches in lowering LDL-cholesterol, triglyceride-rich lipoproteins, inflammation, haemorrheology and Lp(a). The value of adding nicotinic acid to apheresis or to PCSK9 monoclonal antibodies for lowering Lp(a) merits investigation.…”

PCSK9 inhibitors: Going forward and beyond

“…Within just 12 years from the gene discovery, two PCSK9 inhibitors could receive United States of America Food and Drug Administration approval for the treatment of familial hypercholesterolemia and have been shown to be equivalent in reducing LDL and superior in increasing highdensity lipoprotein levels as compared to lipoprotein apheresis. 2,3 In brief, PCSK9 binds to LDL receptors and causes their destruction within lysosomes. Its inhibition would result in the recycling of LDL receptors, which leads to the internalization of more LDL cholesterols and a reduction in the blood levels of LDL.…”